Real‐World Prognostic Analysis of Clinical Characteristics in Extensive‐Stage Small Cell Lung Cancer: A Nomogram for Survival Prediction in Patients Receiving First‐Line Immunochemotherapy With Serplulimab
Cancer Medicine · 2026
DOI: 10.1002/cam4.72130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Ying Zhu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. Hauptthemen laut MEDLINE: Nomograms, Lung Neoplasms, Small Cell Lung Carcinoma, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Extensive‐stage small cell lung cancer (ES‐SCLC) has limited treatment options, with first‐line immunochemotherapy providing modest survival benefits.
Objectives
This single‐center, retrospective study aimed to develop a prognostic nomogram using real‐world data from ES‐SCLC patients treated with serplulimab‐based immunochemotherapy to identify key factors influencing overall survival (OS). Materials and Methods 109 ES‐SCLC patients treated with first‐line immunochemotherapy were analyzed. Baseline clinicopathological characteristics and hematological markers were assessed, and four prognostic factors ‐ liver metastasis, maintenance therapy, albumin level, and neutrophil‐to‐lymphocyte ratio (NLR) ‐ were identified by LASSO regression. A nomogram was constructed to predict 6‐, 12‐, and 24‐month OS rates. The model's performance was validated with C‐index, AUC, calibration curves, and decision curve analysis.
Results
The nomogram effectively stratified patients into low‐, intermediate‐, and high‐risk groups with significant OS differences (log‐rank p < 0.001). Patients with liver metastasis, no maintenance therapy, low albumin levels, and high NLR had worse outcomes. The C‐index for the training and internal validation sets was 0.698 and 0.832, respectively, with AUC values exceeding 0.7 across most time points, suggesting favorable discrimination within this exploratory cohort.
Conclusions
The identified nomogram provides an exploratory real‐world tool for OS estimation in ES‐SCLC patients receiving first‐line serplulimab‐based immunochemotherapy. By integrating baseline clinical factors and treatment‐course information, the model may support dynamic risk stratification and help inform follow‐up intensity, supportive care optimization, and prognostic counseling during routine clinical practice. Further prospective, multicenter external validation and time‐dependent analyses are warranted to confirm and optimize its clinical applicability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
- Hebei Medical University, Shijiazhuang, Hebei, China.
- Department of Internal Medicine, The Second Affiliated Hospital of Xingtai Medical College, Xingtai, Hebei, China.
ORCID-Profile: Ming Zhang, Yuyun Lan, Yarong Wang, Yao Liu, Yibing Liu
Zitieren
APA
Zhu, Y., Li, Z., Zhang, M., Lan, Y., Wang, Y., Liu, Y., & Liu, Y. (2026). Real‐World Prognostic Analysis of Clinical Characteristics in Extensive‐Stage Small Cell Lung Cancer: A Nomogram for Survival Prediction in Patients Receiving First‐Line Immunochemotherapy With Serplulimab. Cancer Medicine. https://doi.org/10.1002/cam4.72130
Vancouver
Zhu Y, Li Z, Zhang M, Lan Y, Wang Y, Liu Y, et al. Real‐World Prognostic Analysis of Clinical Characteristics in Extensive‐Stage Small Cell Lung Cancer: A Nomogram for Survival Prediction in Patients Receiving First‐Line Immunochemotherapy With Serplulimab. Cancer Medicine. 2026. doi:10.1002/cam4.72130
BibTeX
@article{Zhu2026,
author = {Zhu, Ying and Li, Zhongwen and Zhang, Ming and Lan, Yuyun and Wang, Yarong and Liu, Yao and Liu, Yibing},
title = {Real‐World Prognostic Analysis of Clinical Characteristics in Extensive‐Stage Small Cell Lung Cancer: A Nomogram for Survival Prediction in Patients Receiving First‐Line Immunochemotherapy With Serplulimab},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.72130}
}
EUVIMED